MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Gilead Sciences Inc.

Open

SectorGezondheidszorg

102.45 -4.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

100.88

Max

107.3

Belangrijke statistieken

By Trading Economics

Inkomsten

530M

1.8B

Verkoop

29M

7.6B

K/W

Sectorgemiddelde

274.553

57.333

EPS

1.9

Dividendrendement

3.02

Winstmarge

23.557

Werknemers

17,600

EBITDA

-655M

3.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+9.79% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.02%

2.63%

Volgende dividenddatum

26 jun 2025

Volgende Ex Dividend datum

13 jun 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

8.7B

130B

Vorige openingsprijs

106.79

Vorige sluitingsprijs

102.45

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Gilead Sciences Inc. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 20:17 UTC

Winsten

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11 feb 2025, 21:17 UTC

Winsten

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24 apr 2025, 20:08 UTC

Winsten

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Rev $6.67B >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q EPS $1.04 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q EPS $1.04 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Net $1.32B >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24 apr 2025, 20:02 UTC

Winsten

Gilead Sciences 1Q Rev $6.7B >GILD

11 apr 2025, 09:30 UTC

Top Nieuws

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19 mrt 2025, 14:50 UTC

Top Nieuws

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 feb 2025, 22:13 UTC

Marktinformatie
Winsten

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11 feb 2025, 21:06 UTC

Winsten

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Raises Dividend 2.6%>GILD

11 feb 2025, 21:02 UTC

Winsten

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Peer Vergelijking

Prijswijziging

Gilead Sciences Inc. Prognose

Koersdoel

By TipRanks

9.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 116.79 USD  9.79%

Hoogste 140 USD

Laagste 89 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gilead Sciences Inc. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

24 ratings

18

Buy

6

Hold

0

Sell

Technische score

By Trading Central

105 / 106.5Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Very Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.